Study Flags Potential Benefit of Targeted Medication Reviews

The Part D Enhanced Medication Therapy Management Model launched in 2017 with the intention of incentivizing prescription drug plans (PDPs) to investigate new strategies to optimize medication therapy management (MTM) programs and ultimately reduce Medicare costs. This five-year program, launched across five different Part D regions, is about to come to an end, raising questions such as: What are some of the lessons learned? How could expanding the scope of traditional MTM programs improve outcomes?

Health care solutions company Tabula Rasa HealthCare partnered with Blue Cross and Blue Shield Northern Plains Alliance, a model participant, to improve its MTM program. Now, the company has published a series of papers in the American Journal of Managed Care (AJMC) demonstrating how identifying at-risk patients and optimizing medication regimens at the pharmacist level can impact health care costs and outcomes for Medicare beneficiaries.

© 2023 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today